Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection
The study will evaluate the efficacy of switching to a regimen of single antiretroviral lenacapavir (LEN) in combination with two biologics Teropavimab and Zinlirvimab versus continuing on baseline oral ART.
Read more:
- https://www.nejm.org/doi/full/10.1056/NEJMoa2115542
- https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/gilead-presents-positive-proof-of-concept-data-for-investigational-combination-regimen-of-lenacapavir-with-broadly-neutralizing-antibodies-as-a-potent
- https://www.clinicaltrials.gov/study/NCT05729568
- https://www.clinicaltrialsarena.com/news/gilead-sciences-hiv-therapy-trial/